Rodrigo A Cunha Selected Research

alpha,beta-methyleneadenosine 5'-diphosphate

1/2019

Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodrigo A Cunha Research Topics

Disease

29	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 04/2003
14	Gliosis 01/2022 - 10/2009
14	Parkinson Disease (Parkinson's Disease) 01/2020 - 10/2004
13	Neuroinflammatory Diseases 01/2021 - 01/2010
12	Memory Disorders (Memory Loss) 01/2018 - 04/2008
9	Brain Diseases (Brain Disorder) 01/2021 - 05/2011
9	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 06/2005
8	Cognitive Dysfunction 01/2018 - 01/2007
5	Epilepsy (Aura) 01/2021 - 10/2003
5	Ischemia 01/2021 - 05/2011
4	Infections 01/2021 - 01/2016
4	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 11/2020 - 04/2013
3	Ataxia (Dyssynergia) 06/2021 - 03/2017
3	Dyskinesias (Dyskinesia) 01/2021 - 04/2019
3	Anhedonia 01/2021 - 01/2014
3	Inflammation (Inflammations) 01/2020 - 03/2016
3	Mental Disorders (Mental Disorder) 01/2019 - 01/2008
3	Type 2 Diabetes Mellitus (MODY) 01/2018 - 01/2010
3	Dementia (Dementias) 01/2018 - 01/2010
3	Huntington Disease (Huntington's Disease) 07/2015 - 11/2009
3	Amnesia (Dissociative Amnesia) 01/2010 - 01/2007
2	Neoplasms (Cancer) 01/2022 - 10/2020
2	Angelman Syndrome (Syndrome, Angelman) 06/2021 - 12/2020
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2021 - 05/2019
2	Neurodevelopmental Disorders 12/2020 - 11/2019
2	Seizures (Absence Seizure) 06/2020 - 10/2003
2	Neuroblastoma 01/2019 - 06/2014
2	Nervous System Diseases (Neurological Disorders) 10/2018 - 03/2003
2	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 03/2017 - 05/2013
2	Schizophrenia (Dementia Praecox) 12/2015 - 01/2014
2	Amyloid Plaque 01/2015 - 01/2010
1	Iron Deficiencies 02/2022
1	Restless Legs Syndrome (Restless Legs) 02/2022
1	Mood Disorders (Mood Disorder) 01/2022
1	Acute Disease 01/2022
1	Intellectual Disability (Idiocy) 12/2020
1	Binge Drinking 10/2020
1	Periodontal Diseases (Periodontal Disease) 10/2020
1	Wounds and Injuries (Trauma) 05/2019

Drug/Important Bio-Agent (IBA)

30	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2022 - 02/2005
25	Caffeine (No Doz)FDA LinkGeneric 01/2021 - 04/2003
20	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 04/2003
13	Proteins (Proteins, Gene)FDA Link 06/2021 - 03/2007
12	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2012
11	Peptides (Polypeptides)IBA 01/2022 - 04/2008
9	Adenosine Triphosphate (ATP)IBA 01/2021 - 02/2014
9	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 10/2004
8	Glutamic Acid (Glutamate)FDA Link 01/2021 - 10/2003
7	Purinergic P1 Receptors (Adenosine Receptor)IBA 02/2022 - 10/2008
6	Purinergic P1 Receptor AntagonistsIBA 09/2020 - 01/2007
6	SynaptophysinIBA 05/2019 - 10/2009
4	EnzymesIBA 01/2022 - 01/2016
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 10/2009
4	Levodopa (L Dopa)FDA LinkGeneric 01/2021 - 04/2019
4	Brain-Derived Neurotrophic Factor (BDNF)IBA 09/2020 - 01/2013
4	Oxidopamine (6 Hydroxydopamine)IBA 01/2020 - 06/2014
4	Retinaldehyde (Retinal)IBA 10/2017 - 01/2014
4	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 02/2015 - 04/2008
4	Amyloid beta-PeptidesIBA 01/2010 - 01/2007
3	CytokinesIBA 01/2021 - 08/2012
3	Coffee FDA Link 10/2020 - 03/2018
3	Ethanol (Ethyl Alcohol)IBA 10/2020 - 09/2014
3	istradefyllineIBA 01/2020 - 01/2010
3	EndocannabinoidsIBA 01/2019 - 01/2016
3	Qa-SNARE Proteins (Syntaxin)IBA 01/2018 - 10/2009
3	Streptozocin (Streptozotocin)FDA Link 01/2018 - 03/2007
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 03/2003
3	Glial Fibrillary Acidic ProteinIBA 02/2014 - 10/2009
3	Neuroprotective AgentsIBA 10/2009 - 06/2005
2	GlucocorticoidsIBA 01/2022 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2021 - 03/2007
2	Drinking WaterIBA 09/2020 - 01/2010
2	Purinergic P2X7 ReceptorsIBA 01/2020 - 06/2014
2	coomassie Brilliant BlueIBA 01/2020 - 06/2014
2	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 04/2019 - 03/2009
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2019 - 01/2018
2	CannabinoidsIBA 01/2019 - 11/2016
2	anandamide (arachidonylethanolamide)IBA 01/2018 - 11/2016
2	Ataxin-3IBA 03/2017 - 05/2013
2	polyglutamineIBA 03/2017 - 05/2013
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 10/2016 - 01/2015
2	Neurotransmitter Agents (Neurotransmitter)IBA 03/2016 - 05/2012
2	Dizocilpine Maleate (Dizocilpine)IBA 12/2015 - 04/2008
2	LipopolysaccharidesIBA 06/2015 - 04/2011
1	Glycerol (Glycerine)FDA LinkGeneric 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	LigandsIBA 01/2021
1	NeuropeptidesIBA 11/2020
1	MelatoninIBA 01/2020
1	Ziram (Zinc Dimethyldithiocarbamate)IBA 01/2020
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 01/2020
1	PurinesIBA 11/2019
1	GuanosineIBA 05/2019
1	cresyl violetIBA 05/2019
1	alpha,beta-methyleneadenosine 5'-diphosphateIBA 01/2019
1	Adenosine Diphosphate (ADP)IBA 01/2019
1	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2019

Therapy/Procedure

4	Therapeutics 01/2020 - 05/2013